Realm Therapeutics investors itching to sell as lead eczema drug fails phase II study

04:31 EDT 14 Aug 2018 | Proactive Investors

Patients using Realm’s PR022 drug saw no real improvement in their eczema compared with what would be expected without any treatment at all

More From BioPortfolio on "Realm Therapeutics investors itching to sell as lead eczema drug fails phase II study"